Metformin improves skeletal muscle microvascular insulin resistance in metabolic syndrome

Am J Physiol Endocrinol Metab. 2022 Feb 1;322(2):E173-E180. doi: 10.1152/ajpendo.00287.2021. Epub 2021 Dec 27.

Abstract

Microvascular insulin resistance is present in metabolic syndrome and may contribute to increased cardiovascular disease risk and the impaired metabolic response to insulin observed. Metformin improves metabolic insulin resistance in humans. Its effects on macro and microvascular insulin resistance have not been defined. Eleven subjects with nondiabetic metabolic syndrome were studied four times (before and after 12 wk of treatment with placebo or metformin) using a crossover design, with an 8-wk washout interval between treatments. On each occasion, we measured three indices of large artery function [pulse wave velocity (PWV), radial pulse wave separation analysis (PWSA), brachial artery endothelial function (flow-mediated dilation-FMD)] as well as muscle microvascular perfusion [contrast-enhanced ultrasound (CEU)] before and at 120 min into a 150 min, 1 mU/min/kg euglycemic insulin clamp. Metformin decreased body mass index (BMI), fat weight, and % body fat (P < 0.05, each), however, placebo had no effect. Metformin (not placebo) improved metabolic insulin sensitivity, (clamp glucose infusion rate, P < 0.01), PWV, and FMD after insulin were unaffected by metformin treatment. PWSA improved with insulin only after metformin P < 0.01). Insulin decreased muscle microvascular blood volume measured by contrast ultrasound both before and after placebo and before metformin (P < 0.02 for each) but not after metformin. Short-term metformin treatment improves both metabolic and muscle microvascular response to insulin. Metformin's effect on microvascular insulin responsiveness may contribute to its beneficial metabolic effects. Metformin did not improve aortic stiffness or brachial artery endothelial function, but enhanced radial pulse wave properties consistent with relaxation of smaller arterioles.NEW & NOTEWORTHY Metformin, a first-line treatment for type 2 diabetes, is often used in patients with insulin resistance and metabolic syndrome. Here, we provide the first evidence for metformin improving muscle microvascular insulin sensitivity in insulin-resistant humans. Simultaneously, metformin improved muscle glucose disposal, supporting a close relationship between insulin's microvascular and its metabolic actions in muscle. Whether enhanced microvascular insulin sensitivity contributes to metformin's ability to decrease microvascular complications in diabetes remains to be resolved.

Keywords: contrast-enhanced ultrasound; insulin resistance; metformin; microvasculature.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Arteries / drug effects
  • Arteries / metabolism
  • Blood Flow Velocity / drug effects
  • Blood Glucose / metabolism
  • Body Mass Index
  • Endothelium, Vascular / drug effects
  • Endothelium, Vascular / metabolism
  • Female
  • Glucose Clamp Technique
  • Humans
  • Hypoglycemic Agents / administration & dosage*
  • Insulin / administration & dosage
  • Insulin / metabolism
  • Insulin Resistance*
  • Male
  • Metabolic Syndrome / drug therapy*
  • Metabolic Syndrome / metabolism*
  • Metformin / administration & dosage*
  • Microcirculation / drug effects*
  • Middle Aged
  • Muscle, Skeletal / blood supply*
  • Muscle, Skeletal / metabolism*
  • Pulse Wave Analysis
  • Random Allocation
  • Treatment Outcome
  • Vascular Stiffness / drug effects

Substances

  • Blood Glucose
  • Hypoglycemic Agents
  • Insulin
  • Metformin